205 related articles for article (PubMed ID: 11748952)
21. Is There a Difference in the Clinical Efficacy of Diosmin and Micronized Purified Flavonoid Fraction for the Treatment of Chronic Venous Disorders? Review of Available Evidence.
Cazaubon M; Benigni JP; Steinbruch M; Jabbour V; Gouhier-Kodas C
Vasc Health Risk Manag; 2021; 17():591-600. PubMed ID: 34556990
[TBL] [Abstract][Full Text] [Related]
22. [Evaluation of clinical efficacy of a venotonic drug: lessons of a therapeutic trial with hemisynthesis diosmin in "heavy legs syndrome"].
Carpentier PH; Mathieu M
J Mal Vasc; 1998 Apr; 23(2):106-12. PubMed ID: 9608923
[TBL] [Abstract][Full Text] [Related]
23. Pharmacologic aspects of a phlebotropic drug in CVI-associated edema.
Ramelet AA
Angiology; 2000 Jan; 51(1):19-23. PubMed ID: 10667639
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and tolerability of a red-vine-leaf extract in patients suffering from chronic venous insufficiency--results of a double-blind placebo-controlled study.
Rabe E; Stücker M; Esperester A; Schäfer E; Ottillinger B
Eur J Vasc Endovasc Surg; 2011 Apr; 41(4):540-7. PubMed ID: 21239190
[TBL] [Abstract][Full Text] [Related]
25. The Benefits of Micronized Purified Flavonoid Fraction (MPFF) Throughout the Progression of Chronic Venous Disease.
Nicolaides AN
Adv Ther; 2020 Feb; 37(Suppl 1):1-5. PubMed ID: 31970659
[TBL] [Abstract][Full Text] [Related]
26. Micronized purified flavonoid fraction (MPFF): a review of its pharmacological effects, therapeutic efficacy and benefits in the management of chronic venous insufficiency.
Katsenis K
Curr Vasc Pharmacol; 2005 Jan; 3(1):1-9. PubMed ID: 15641940
[TBL] [Abstract][Full Text] [Related]
27. Endothelial activation response to oral micronised flavonoid therapy in patients with chronic venous disease--a prospective study.
Shoab SS; Porter J; Scurr JH; Coleridge-Smith PD
Eur J Vasc Endovasc Surg; 1999 Apr; 17(4):313-8. PubMed ID: 10204053
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of orally administered extract of red vine leaf AS 195 (folia vitis viniferae) in chronic venous insufficiency (stages I-II). A randomized, double-blind, placebo-controlled trial.
Kiesewetter H; Koscielny J; Kalus U; Vix JM; Peil H; Petrini O; van Toor BS; de Mey C
Arzneimittelforschung; 2000 Feb; 50(2):109-17. PubMed ID: 10719612
[TBL] [Abstract][Full Text] [Related]
29. Meta-analysis of the impact of the principal venoactive drugs agents on malleolar venous edema.
Allaert FA
Int Angiol; 2012 Aug; 31(4):310-5. PubMed ID: 22801396
[TBL] [Abstract][Full Text] [Related]
30. Micronized purified flavonoid fraction-based conservative treatment of chronic venous disease in a real-world setting.
Bogachev V; Boldin B; Turkin P; Samenkov A; Dzhenina O
Future Cardiol; 2022 Sep; 18(10):777-785. PubMed ID: 36004765
[TBL] [Abstract][Full Text] [Related]
31. Controlled studies of Daflon 500 mg in chronic venous insufficiency.
Geroulakos G; Nicolaides AN
Angiology; 1994 Jun; 45(6 Pt 2):549-53. PubMed ID: 8203786
[TBL] [Abstract][Full Text] [Related]
32. Mechanisms in experimental venous valve failure and their modification by Daflon 500 mg.
Pascarella L; Lulic D; Penn AH; Alsaigh T; Lee J; Shin H; Kapur V; Bergan JJ; Schmid-Schönbein GW
Eur J Vasc Endovasc Surg; 2008 Jan; 35(1):102-10. PubMed ID: 17890112
[TBL] [Abstract][Full Text] [Related]
33. Venous leg ulcer: a meta-analysis of adjunctive therapy with micronized purified flavonoid fraction.
Coleridge-Smith P; Lok C; Ramelet AA
Eur J Vasc Endovasc Surg; 2005 Aug; 30(2):198-208. PubMed ID: 15936227
[TBL] [Abstract][Full Text] [Related]
34. Improving Chronic Venous Disease Management with Micronised Purified Flavonoid Fraction: New Evidence from Clinical Trials to Real Life.
Lurie F; Branisteanu DE
Clin Drug Investig; 2023 Jun; 43(Suppl 1):9-13. PubMed ID: 37171748
[TBL] [Abstract][Full Text] [Related]
35. Double blind study of the pharmacodynamic and clinical activities of 5682 SE in venous insufficiency. Advantages of the new micronized form.
Cospite M; Dominici A
Int Angiol; 1989; 8(4 Suppl):61-5. PubMed ID: 2698903
[TBL] [Abstract][Full Text] [Related]
36. Clinical efficacy of once-daily micronized purified flavonoid fraction 1000 mg tablet in patients with symptomatic chronic venous disease.
Kirienko A; Radak D; Maggioli A
Curr Med Res Opin; 2019 Mar; 35(3):553-557. PubMed ID: 29992831
[TBL] [Abstract][Full Text] [Related]
37. New Perspectives on Micronised Purified Flavonoid Fraction in Chronic Venous Disease: From Microvalves to Clinical Effectiveness.
Bouskela E; Lugli M; Nicolaides A
Adv Ther; 2022 Oct; 39(10):4413-4422. PubMed ID: 35951224
[TBL] [Abstract][Full Text] [Related]
38. Venoruton vs Daflon: evaluation of effects on quality of life in chronic venous insufficiency.
Cesarone MR; Belcaro G; Pellegrini L; Ledda A; Vinciguerra G; Ricci A; Di Renzo A; Ruffini I; Gizzi G; Ippolito E; Fano F; Dugall M; Acerbi G; Cornelli U; Hosoi M; Cacchio M
Angiology; 2006; 57(2):131-8. PubMed ID: 16518519
[TBL] [Abstract][Full Text] [Related]
39. Advantage of a micronized flavonoidic fraction (Daflon 500 mg) in comparison with a nonmicronized diosmin.
Amato C
Angiology; 1994 Jun; 45(6 Pt 2):531-6. PubMed ID: 8203783
[TBL] [Abstract][Full Text] [Related]
40. Clinical benefits of Daflon 500 mg in the most severe stages of chronic venous insufficiency.
Ramelet AA
Angiology; 2001 Aug; 52 Suppl 1():S49-56. PubMed ID: 11510597
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
